Welcome to our dedicated page for Unity Biotechnology news (Ticker: UBX), a resource for investors and traders seeking the latest updates and insights on Unity Biotechnology stock.
Unity Biotechnology, Inc. (NASDAQ: UBX) is a leading biotechnology company focused on developing innovative therapeutics aimed at extending human healthspan by targeting age-related diseases. The company's pioneering approach centers on creating senolytic medicines, which selectively eliminate senescent cells – cells that contribute to aging and various diseases. Unity's initial efforts are directed toward treating conditions such as osteoporosis, eye diseases, and pulmonary diseases.
Unity’s main drug candidates include:
- UBX1325: A promising treatment for age-related eye diseases, including diabetic macular edema (DME). UBX1325 recently demonstrated positive results in the Phase 2 ENVISION study, maintaining vision gains and significantly reducing anti-VEGF treatment needs in patients with wet AMD.
- UBX2089: A circulating hormone being studied for multiple neurological conditions.
- UBX2050: Another investigational drug aimed at age-associated diseases.
Recently, Unity announced the successful results from Part B of the Phase 2 ENVISION study for UBX1325, highlighting its safety and efficacy in maintaining visual acuity and reducing the treatment burden for patients with wet AMD who were not receiving optimal benefits from ongoing anti-VEGF therapy. The study showed that 40% of UBX1325-treated patients did not require anti-VEGF rescue through 48 weeks.
Unity's current focus is on its DME program, where UBX1325 showed a statistically significant improvement in visual acuity during the Phase 2 BEHOLD study. The company has initiated a Phase 2b study and plans to randomize the first patient in Q4 2023. Additional data from the ENVISION study is expected to be presented at upcoming medical conferences.
About the ENVISION Study: The Phase 2 ENVISION study is a multi-center, randomized, double-masked, active-controlled study evaluating the safety, tolerability, efficacy, and durability of UBX1325 in combination with aflibercept for patients with neovascular AMD.
For more detailed information, visit www.unitybiotechnology.com.
UNITY Biotechnology, a biotechnology firm focused on developing therapeutics to combat aging, has granted a stock-based award of 30,000 shares to a new employee from June 14 to June 28, 2022. This grant, which includes options to purchase the same amount of stock, is made under the UNITY 2020 Employment Inducement Incentive Plan. This plan is designed to attract new talent, complying with Nasdaq Rule 5635(c)(4). UNITY aims to create medicines that target age-related diseases, particularly in ophthalmology and neurology.
UNITY Biotechnology, Inc. (NASDAQ: UBX) has appointed Michael Samar as chair of the audit committee and member of the compensation committee. Samar, currently CFO at Assembly Bio, brings extensive biotech finance experience. CEO Anirvan Ghosh highlights Samar’s strategic contributions as crucial for progressing UBX1325 studies, targeting diabetic macular edema (DME) and age-related macular degeneration (AMD). The announcement coincides with Graham Cooper stepping down, who was acknowledged for his significant contributions. UNITY aims to develop therapeutics to combat diseases of aging.
UNITY Biotechnology, Inc. (Nasdaq: UBX) announced that its senior management team will provide a corporate update at the UBS 2022 Global Healthcare Conference on May 25, 2022, at 11:30 AM ET. The event will be virtual and accessible via the UBS conference portal. An archived replay will be available for 90 days.
UNITY focuses on developing therapeutics to address aging diseases, particularly through the elimination of senescent cells.
UNITY Biotechnology has completed enrollment in its BEHOLD Phase 2 clinical trial for UBX1325 targeting diabetic macular edema (DME) and dosed the first patient in the ENVISION trial for wet age-related macular degeneration (wAMD). 12-week safety and efficacy data from BEHOLD is anticipated by mid-2022, with 16-week results from ENVISION expected in Q4 2022. As of March 31, 2022, the company held $79.2 million in cash, sufficient to fund operations through Q1 2023. Operating loss for Q1 2022 was $18.9 million, up from $15.8 million in Q1 2021.
UNITY Biotechnology announced significant findings at the ARVO 2022 Annual Meeting regarding its investigational drug UBX1325 for diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The Phase 1 study showed that most patients experienced rapid improvements in best corrected visual acuity (BCVA) and maintained central subfield thickness over 24 weeks. A symposium discussed the role of cellular senescence in ocular diseases, reinforcing the potential of UBX1325 as a transformative treatment. Initial results from Phase 2 studies are expected later this year.
UNITY Biotechnology, Inc. (UBX) announced the presentation of clinical data from the Phase 1 study of its senolytic candidate, UBX1325, targeting diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The findings will be showcased at the ARVO 2022 Annual Meeting from May 1-4, where experts will discuss cellular senescence's role in eye diseases. UBX1325 showed a favorable safety profile with sustained visual acuity improvements over 24 weeks following a single dose. This investigational compound aims to transform outcomes for patients suffering from age-related eye diseases.
UNITY Biotechnology announced the commencement of its Phase 2 clinical trial, ENVISION, evaluating UBX1325 for wet age-related macular degeneration (wAMD). The trial aims to enroll 46 patients to assess the drug's safety and efficacy compared to aflibercept. Positive results from the Phase 1 study showed increased visual acuity in most patients at 24 weeks. Results from the ENVISION study are expected in Q4 2022, furthering prospects for UBX1325 as a transformative therapy for wAMD.
UNITY Biotechnology has completed enrollment for its Phase 2 clinical trial, BEHOLD, studying UBX1325 for diabetic macular edema (DME). The trial involves 65 patients and focuses on evaluating the safety and efficacy of a single 10 mcg dose. Results are expected in 12 weeks and 24 weeks. Preliminary Phase 1 data indicates that UBX1325 may offer a novel treatment option for patients unresponsive to current therapies. The goal is to improve outcomes in age-related ocular diseases, including DME and age-related macular degeneration (AMD).
UNITY Biotechnology, Inc. (NASDAQ:UBX) reported its financial results for Q4 and the full year 2021, highlighting a refined pipeline strategy with a focus on UBX1325, designed to treat diabetic macular edema (DME) and age-related macular degeneration (AMD). The company posted a 2021 operating loss of $56.7 million, down from $93.9 million in 2020. Cash and equivalents stood at $90.1 million, expected to fund operations into Q1 2023. Upcoming milestones include Phase 2 safety and efficacy data for UBX1325 expected by mid and end of 2022.
UNITY Biotechnology (NASDAQ: UBX) will present a corporate update at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 11:10 a.m. ET. The event will be virtual, and a replay will be accessible for 90 days afterward. UNITY focuses on developing therapeutics aimed at slowing, halting, or reversing diseases associated with aging, particularly in age-related ophthalmologic and neurologic conditions. Interested investors can access the presentation through the Cowen conference portal or their website.
FAQ
What is the current stock price of Unity Biotechnology (UBX)?
What is the market cap of Unity Biotechnology (UBX)?
What is Unity Biotechnology's primary focus?
What diseases is Unity Biotechnology targeting?
What is UBX1325?
What were the latest results from the ENVISION study?
What are the current projects of Unity Biotechnology?
Where can I find more information about Unity Biotechnology?
What is the significance of senolytic medicines?
Has UBX1325 been approved for use?
What is the expected timeline for the ASPIRE study?
What partnerships does Unity Biotechnology have?
